and/or regurgitation) and impair quality of life may be indicative of an inadequate response. 10 Multiple elements can contribute to breakthrough symptoms, including issues with PPI compliance and dosing, persistence of reflux events (acidic, weakly acidic, bile, pepsin or gas), greater proximal extent of reflux, impaired oesophageal mucosal integrity, chemical or mechanical hypersensitivity to refluxates and psychological comorbidity. [10] [11] [12] GERD patients with an unsatisfactory symptomatic response can be broadly categorised as "typical reflux" (abnormal oesophageal acid exposure, positive symptom-reflux association),
"hypersensitive" (normal acid exposure, positive symptom-reflux association) or functional heartburn (normal acid exposure, negative symptom-reflux association). 12, 13 Symptomatic breakthrough in non-erosive reflux disease (NERD)
occurs primarily with regard to pathological postprandial reflux. 14 In untreated individuals, the "acid pocket" forms on top of food-buffered gastric contents and acts as a highly acidic source of postprandial reflux. 15, 16 A postprandial layer of gastric secretion also exists in PPI-treated patients; it is less acidic than the acid pocket (~pH 3.9 vs~0.9) [15] [16] [17] but remains the source of reflux after meals. 18, 19 Alginates are interesting candidates for use as an add-on therapy 11, 16 as they act in a complementary way to PPIs by directly capping postprandial reflux. 18 The alginate-antacid formulation, Gaviscon Double Action (Gaviscon DA; RB, Slough, UK), has been shown to co-localise and eliminate the acid pocket in GERD patients. 18, 20 The gel-like alginate raft forms close to the gastrooesophageal junction and is able to preferentially reflux in place of gastric contents. 21 Furthermore, recent in vitro data suggest that alginate may bind to the oesophageal mucosa and exhibit mucosal protective qualities. [22] [23] [24] Previous studies indicate that addition of alginate may help maintain symptom control at initiation of PPI treatment 25, 26 and when stepping down to a maintenance dose or discontinuing PPIs, [27] [28] [29] [30] [31] a period when rebound acid hypersecretion can be problematic. 30 The only published randomised clinical trial to investigate alginate (Gaviscon Advance) as add-on therapy in patients with breakthrough symptoms 32 demonstrated a reduction in reflux symptoms using the validated Heartburn Reflux Dyspepsia Questionnaire (HRDQ) daily recall patient questionnaire 33 as the outcomes measure. This study reported absolute changes in HRDQ scores from baseline, with significantly greater reductions being observed for add-on Gaviscon Advance vs placebo. Since publication of the study, the HRDQ scale has been further evaluated and clinically relevant response status has been defined. 33 An HRDQ cut-off score of 0.70 was selected based on correlation with the established ReQuest symptom threshold of 0.95. The 0.70 cut-off for definition of a "bad day" was evaluated and response was defined as reduction of three or more days in a week with an HRDQ score >0.7.
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Here we report the results from two studies, an exploratory study measuring change in HRDQ scores and a confirmatory study using the HRDQ response status classification, to determine whether add-on therapy with the alginate-antacid, Gaviscon DA Liquid, can reduce the burden of breakthrough symptoms in PPI-treated patients. 
| METHODS

| Study design
At the screening visit, eligible patients were enrolled in a 7-day run-in period during which they continued their once-daily PPI and completed the HRDQ to assess reflux symptoms and a diary card to record compliance with PPI treatment and satisfaction, every day ( Figure 1 ). Following the 7-day run-in, patients were reassessed for eligibility to enter the treatment phase of the trial and completed the Reflux Disease Questionnaire (RDQ) 35, 36 to determine (baseline) satisfaction with medication over the previous 7 days. Patients, who met the symptom threshold for eligibility (Exploratory study: patients with at least one reflux symptom of at least moderate intensity during run-in and a summarised 7-day HRDQ score for heartburn and/or regurgitation of at least 18, e.g. In the confirmatory study, patient numbers 001 to 544 were allocated in randomised blocks using 1:1 treatment allocation. Only complete blocks were issued to each study centre. At randomisation (both studies), patients were allocated a unique 3-digit patient randomisation number in numerical sequence. Treatments were issued in this sequence to ensure randomisation. All study personnel and participants were blinded to treatment allocation. The master code for the randomisation schedule was held by RB Investigational Material Supplies Unit. The investigator was supplied with the randomisation code for each subject as individually sealed envelopes, which were broken only in the event of an emergency and checked regularly by the study monitor. The randomisation code for all patients was broken only after the database was locked.
Patients were instructed to take 20 mL of suspension (Exploratory study, dosing cups provided with 150 mL bottles; Confirmatory study, 10 mL sachets provided), four times a day (30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before going to bed), while continuing with their regular PPI. Patients recorded intake of study medication and PPI on the diary card and compliance was assessed according to the number of used/empty medication bottles (exploratory study) or used/unused sachets (confirmatory study) returned at the final study visit, supported by the number of doses entered onto the diary card. Patients, who had taken fewer than 75% of the required doses of study medication, were excluded from the per protocol analysis.
| Outcome measures
Primary efficacy data were based on the HRDQ, 33 a measure designed specifically to capture symptoms that are most relevant for patients with uncontrolled GERD symptoms while taking daily PPIs.
The HRDQ was adapted from the two most extensively tested patient-reported outcome measures, the RDQ 35, 36 and ReQuest 37 questionnaires which, while well-validated, are not designed for patients with residual GERD symptoms while on therapy. The RDQ is a 12-item questionnaire designed to retrospectively assess
(1-week re-call 35, 38 ) the frequency and severity of heartburn, regurgitation and dyspeptic symptoms of GERD in primary care. 36 The HRDQ differs from the RDQ in that the questionnaire is shorter, completed daily and also assesses night-time events and total duration of symptoms. 33 In the exploratory study, daily HRDQ scores were calculated by multiplying severity score (0-3) with frequency score (0-6), giving a score from 0 to 18 for each individual symptom, as described previously. 32 For the confirmatory study, the primary endpoint was changed to a responder analysis in line with European
Medicines Agency guidance. 39 The scoring method was based on the following formula:
Patient on once-daily PPI with breakthrough symptoms 7 day run-in period with PPI Symptoms assessed using HRDQ 37 Based on this scoring algorithm, the total range of the HRDQ daily score was from 0 to 4 and the validated cut-off for a bad day was daily score >0.70.
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A day with this cut-off may correspond, for example, to two episodes of mild heartburn and one episode of mild regurgitation. While this may seem a low threshold for an acceptable symptom burden, it is important to remember that the HRDQ captures ongoing reflux symptoms in patients with known GERD already on PPI therapy.
Response is defined as reduction of three or more days in a week with an HRDQ score >0.7. 
| Primary endpoints
The primary endpoint in the exploratory study was the change in HRDQ scores (heartburn and regurgitation only, mean over the 7 days of treatment) from baseline (mean over the 7 days of run-in).
The primary endpoint in the confirmatory study was "response," i.e.
whether the patient achieved a reduction of at least 3 days in the number of days with an HRDQ score >0.70 (heartburn and regurgitation) during the 7-day treatment period compared to the 7-day run-in period. If there were more than 7 days of HRDQ scores within the treatment period then only the last 7 days were used.
| Secondary endpoints
Secondary endpoints were change in HRDQ score (mean over 7 days of treatment) from baseline (mean over 7 days of run-in) for individual symptoms (heartburn, regurgitation and dyspepsia, and in addition for the confirmatory study, heartburn and regurgitation combined), change in the daily frequency/severity of individual symptoms (heartburn, regurgitation and, for exploratory study only, dyspepsia), presence of any night-time symptoms and change in the number of nights with symptoms, change in mean daily duration of symptoms, the number of symptom-free days during treatment and change in score for overall satisfaction from baseline. The confirmatory study also included change from baseline in RDQ symptom scores and frequency/severity scores (heartburn and regurgitation combined/independently and dyspepsia) and the exploratory study included change in ReQuest GI scores (short version) from baseline.
| Statistical analysis 2.5.1 | Sample size
Sample size estimates for the confirmatory study were calculated using data from the Gaviscon DA exploratory study and a previously reported placebo-controlled alginate study (Gaviscon Advance, RB, UK) that also used the HRDQ. 32 When data from these two studies were pooled for patients that had at least 3 days with an HRDQ score (heartburn and regurgitation) >0.70 over the 7-day run-in period (120/134 for Gaviscon Advance study and 49/52 for Gaviscon DA exploratory study), the percentage of patients that responded was 63% for Gaviscon vs 32% for placebo. It was estimated that 128 patients per treatment group (256 overall) in the primary analysis of the confirmatory study would provide 90% power to detect a significant difference at the two-sided 5% level. To allow for a 5% drop out rate from the safety to intention-to-treat (ITT) population, it was calculated that 136 patients per group (272 overall) were required.
| Endpoint analyses
Efficacy and baseline data were analysed for the ITT population, which consisted of all patients who were recruited to the study and had at least 1 day of complete HRDQ data (severity and frequency scores for both heartburn and regurgitation) for both the run-in and treatment periods. The change in the mean daily HRDQ score (heartburn and regurgitation) from baseline to postbaseline was analysed using an analysis of covariance (ANCOVA) with treatment and centre as fixed effects and baseline HRDQ score as a covariate. The difference between least squares means (Gaviscon DA-placebo) was calculated along with 95% confidence intervals (95% CI).
Response rates were analysed using a logistic regression model | 1527
The 3 | RESULTS
| Exploratory study
A total of 83 patients were screened during the 7-day run-in period.
Of these, 52 met the criteria and were randomised to receive Gaviscon DA Liquid (n=26) or placebo (n=26). All patients received at least one dose of study medication, and none of the patients withdrew prematurely from the study. There were no significant differences between the demographics and baseline characteristics (Table 1) .
Overall, all patients were considered to be compliant to the study medication, taking ≥75% of the scheduled dose, and compliance was similar between the Gaviscon and placebo groups.
| Primary efficacy analysis
Mean HRDQ scores (heartburn and regurgitation) at baseline were similar in both treatment groups (Table 2) . Scores were significantly reduced from baseline to post-baseline in both treatment groups (P<.0001 for both), with the Gaviscon DA group showing statistically significantly greater reductions compared with the placebo group (P=.012, Table 2 ).
| Secondary efficacy analysis
Mean baseline HRDQ scores for the individual symptoms of heartburn, regurgitation and dyspepsia were similar in both treatment groups. Analyses of the HRDQ scores for the individual symptoms before and after treatment, including group comparisons, are shown in Table S1 for a summary of primary and secondary endpoints expressed as HRDQ symptom score change and percentage change from baseline.)
| Responder analysis
The percentage of patients with a reduction of at least 3 days in the number of days with HRDQ score (heartburn and regurgitation) >0.7
during the 7-day treatment period compared to the run-in period, was significantly greater for Gaviscon DA (75%) than for placebo (36%), P=.005 (Figure 2 ).
| Confirmatory study
In total 396 patients were screened, of these, 263 met the selection criteria and were randomised to receive Gaviscon DA (n=131) or placebo (n=132). All patients except one randomised to the placebo group who was lost to follow-up (not known whether any study medication was taken) received at least one dose of study medication. One patient from the placebo group and three patients from the Gaviscon group withdrew prematurely from the study due to AEs. Therefore, 131 patients from each group were included in the ITT population and the number of patients completing the study was 128 and 130 in the Gaviscon and placebo groups, respectively. There was no significant difference in baseline characteristics of the Gaviscon and placebo groups (Table 1) . Compared with the exploratory study, the patient population of the confirmatory study had a higher mean age and a greater use of pantoprazole and second-generation PPIs (esomeprazole and rabeprazole). Five patients (2.1%) were noncompliant, taking <75% of the scheduled treatment dose, four patients (3.3%) in the Gaviscon group and one patient (0.8%) in the placebo group. 
T A B L E 1 Demographic data and subject characteristics at baseline in the intention-to-treat (ITT) populations
| Primary efficacy analysis
The percentage of patients considered responders, achieving a reduction of at least 3 days in the number of days the HRDQ score (heartburn and regurgitation) >0.7 during the 7-day treatment period vs run-in period, was 51% (n=67) for Gaviscon DA and 48% (n=63) for placebo ( Figure 2 As the exploratory study reported a significantly greater response in the Gaviscon group compared with placebo, potential causes for the variability in results between this study and the confirmatory study were investigated. It was found that the mean baseline dyspepsia score was significantly greater in the Gaviscon arm compared with the placebo arm in the confirmatory study.
| Secondary efficacy analysis
Secondary endpoints followed a similar pattern to the primary end- EXPLORATORY CONFIRMATORY PPI + Gaviscon PPI + placebo F I G U R E 2 Percentage of patients responding after 7 days of add-on Gaviscon DA or placebo treatment in the exploratory study (n=49) and Confirmatory study (n=262). Responders were defined as those patients with a reduction of at least 3 days with HRDQ score (heartburn and regurgitation combined) >0.7 to post-baseline were not significantly different for the Gaviscon and placebo groups (See Table S1 for a summary of primary and secondary endpoints expressed as HRDQ symptom score change and percentage change from baseline).
| Adverse events
Adverse events in the exploratory study were reported by five patients (19.2%) in the placebo group, and seven patients (26.9%) in the Gaviscon group, all of which were reported to be mild. One AE (gastrointestinal disorder) in the Gaviscon group was considered as being at least possibly related to study treatment. There were no withdrawals due to AEs. In the confirmatory study, AEs were recorded by 25.2% of patients in the Gaviscon group and 23.5% of patients in the placebo group with events in 24/263 patients (9.1%) being considered drug-related. None of the AEs were serious. AEs led to four withdrawals from the confirmatory study, three patients from the Gaviscon group and one patient from the placebo group.
These events comprised upper abdominal pain, defecation urgency and diarrhoea in the Gaviscon group and nausea in the placebo group.
| DISCUSSION
The confirmatory study of add-on treatment with an alginate-antacid suspension was unable to confirm the significant treatment difference vs placebo that was observed in small-scale trials 32 in patients with symptoms despite standard-dose PPI treatment.
Alginates are a well-established and effective, treatment for mildto-moderate symptomatic GERD. 40, 41 They represent a potentially useful and complementary approach to acid suppression due to their direct action at the gastro-oesophageal junction. 18 Our randomised studies assessed a 7-day treatment with add-on alginate, which should be adequate to reveal therapeutic benefit from a rapid-acting, on-demand therapy. The nonsystemic, direct action of Gaviscon means that it is not required to reach steady-state for maximal efficacy. Indeed, the small randomised exploratory study using this treatment strategy demonstrated lower total reflux symptom burden with add-on Gaviscon vs a matched placebo. This finding adds to a body of clinical evidence demonstrating that add-on alginate can help resolve symptoms at various stages of management. [25] [26] [27] [28] [29] [30] [31] A previous trial of untreated NERD patients with moderate to severe heartburn who were randomised to either omeprazole alone or omeprazole plus alginate found that complete resolution of heartburn for at least 7 consecutive days was achieved by 56.7% of those co-prescribed alginate vs 25.7% taking once-daily omeprazole alone after 4 weeks of treatment (P<.05). 26 More recently, a placebo-controlled study of 136 patients with breakthrough symptoms demonstrated significantly greater symptom reduction for patients treated with add-on Gaviscon Advance aniseed liquid (a concentrated alginate formulation) compared with a matched placebo. 32 This previously reported study 32 and the Gaviscon DA exploratory study described here, measured absolute changes in HRDQ symptom scores from baseline. When post hoc responder rate analyses were T A B L E 4 Comparison of response rates across three randomised Gaviscon studies. Data from the Gaviscon DA exploratory study and a previously reported Gaviscon Advance study 32 were re-analysed to determine response rates (percentage of patients achieving a reduction ≥3 days with HRDQ [heartburn and regurgitation] >0.70).
Study
Patients who responded (%) T A B L E 3 Confirmatory study: baseline and post-treatment HRDQ scores and group comparisons (ITT). Mean daily HRDQ scores (based on the validated scoring algorithm giving a daily HRDQ score from 0 to 4 33 ) and ANCOVA analysis for the difference between the Gaviscon DA and placebo groups from baseline to post-baseline carried out for both studies, using the updated HRDQ algorithm that was used for the confirmatory study, 33 both data sets revealed significantly greater responses for active treatment vs placebo (Table 4) . Compared with these studies, the Gaviscon DA confirmatory study had a reduced active treatment response and a noticeably greater placebo response rate, so, while add-on Gaviscon reduced symptoms from baseline, it failed to demonstrate a significant treatment difference vs placebo.
Comparison of the three randomised trials (Table 4 ) also shows a considerably higher active response rate in Gaviscon DA exploratory study (75%) compared with that in the other two studies (56% and 51%). This may be related to patients with confirmed hiatus hernia being excluded. Patients with hiatus hernia are known to have more severe reflux disease, both in terms of reflux frequency and the ability to clear acid, with symptoms that are more resistant to treatment. 42 As the hiatus hernia status of many PPI-treated patients in medical practice is not known, it was decided not to exclude these patients from the confirmatory study.
All three studies used a placebo formulation that matched the Subclassification of NERD patients using pH-impedance testing shows that around a quarter of patients have functional heartburn. 13 Functional heartburn is not related to reflux, responds poorly to acid suppressive therapy and has a similar psychopathology to functional dyspepsia. 10 In fact, some dyspeptic symptoms have been proposed Alginate-based therapies, like Gaviscon, have proven efficacy for resolution of reflux symptoms vs both placebo and antacids in the general GERD patient population. 40 However, the exaggerated placebo response and lack of treatment difference between add-on Gaviscon DA and placebo in the confirmatory study emphasises the difficulty in predicting response to treatment in the heterogeneous, patient population with insufficient response to PPIs. The overall results from the three randomised studies provide additional evidence that add-on alginate may help reduce the burden of persistent reflux-related symptoms for a proportion of patients but further work is required to identify those who are most likely to benefit from this intervention. Bytzer has served as a speaker, a consultant and an advisory board member for RB and has also received research funding from RB.
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